Ibrutinib (PCI-32765)

For research use only. Not for use in humans.

製品コードS2680

CAS No. 936563-96-1

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

サイズ

価格(税別)

10mM (1mL in DMSO)	JPY 47100
5mg	JPY 30200
50mg	JPY 163000
200mg	JPY 412000

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297|電子メール：[email protected]|よく尋ねられる質問

文献中Selleckの製品使用例(483)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

製品説明

ターゲット

BTK ^[1] (Cell-free assay)	BLK ^[1] (Cell-free assay)	Bmx ^[1] (Cell-free assay)	CSK ^[1] (Cell-free assay)	FGR ^[1] (Cell-free assay)	もっとクリックする
0.5 nM	0.5 nM	0.8 nM	2.3 nM	2.3 nM	もっとクリックする

体外試験

Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk's physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. ^[1] Ibrutinib exhibits a significant dose-dependent and time-dependent induction of cytotoxicity in chronic lymphocytic leukemia (CLL) cells. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling. ^[2] A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2.6 nM, 0.5 nM and 3.9 nM, respectively. ^[3]

細胞データ

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human Rec1 cells	M{XDc2Z2dmO2aX;uJIF{e2G7	NYfudI9rOi53IN88US=>	NVK0VZd1PiCq	MWfJcohq[mm2aX;uJI9nKEy7bjDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iUnXjNUBk\WyuczDheEAzNjVidV2gbY5kfWKjdHXkJIZweiB4IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ{Mki3O{c,OjV{MkK4O\|c9N2F-
human WSU-NHL cells	NEWwd3pEgXSxdH;4bYPDqGG\|c3H5		MnfJO\|IhcA>?	NVu4ZlJbS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hX1OXLV7IUEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlA6KM7:TR?=	MkXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human SU-DHL6 cells	M321cGN6fG:2b4jpZ:Kh[XO\|YYm=		M{nnclczKGh?	MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTWU1FUEx4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwNUig{txONg>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlzNUK5NUc,OjR7MUWyPVE9N2F-
human DOHH2 cells	NHm3V\|JEgXSxdH;4bYPDqGG\|c3H5		NGexXnY4OiCq	NIXST5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFV0iKMjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkSxJO69VS5?	NXH3fZFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells	MXrGeY5kfGmxbjDhd5NigQ>?		NUe4bW13OSCq	MYTJcohq[mm2aX;uJI9nKEy\Tj3BJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYX\0[ZIhPjBibXnud{BjgSCWUj3GVmVVKEG\|c3H5MEBKSzVyPUCuNkDPxE1w	NXLPd3lLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVg2PDdpPkKxPVU5PTR5PD;hQi=>
human Ramos cells	MYfGeY5kfGmxbjDhd5NigQ>?		NGnnTXQyKGh?	M3r0PWlvcGmkaYTpc44hd2ZiQoTrJIlvKGi3bXHuJHJidW:\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWEyFLXfhcY1iOiCyaH;zdIhwenmuYYTpc44h[XRiVInyNVIyPyCjZoTldkAyKGi{IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqeyxiSVO1NF0yPCCwTT6=	MlvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
human Pfeiffer cells	MVjGeY5kfGmxbjDhd5NigQ>?		M3[1OVczKGh?	NFzLOo1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBR\mWrZn\ldkBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCudX3pcoV{[2WwdDDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yJI5ONg>?	NWrTTlRoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
Sf9 cells	NUPXV2NjTnWwY4Tpc44h[XO\|YYm=		Ml:yNUBp	M17BU2lvcGmkaYTpc44hd2ZiaIXtZY4h\nWubD3s[Y5ofGhiQmTLJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNidYPpcochTkGPLWPyZ5Rq\GVicHXweIll\SCjczDzeYJ{fHKjdHWgZYZ1\XJiNkCgcYlveyCkeTDUVk1HWkWWIFHzd4F697zOIFnDOVA:OC53IH7NMi=>	M4rXXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUW4OVQ4Lz5{MUm1PFU1PzxxYU6=
Sf9 insect cells	MVrGeY5kfGmxbjDhd5NigQ>?		NFjtNJM3OCCvaX7z	NUHOXWd{UUN3MDC9JFAvODByMzFOwG0>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
sf9 cells	Mk\OSpVv[3Srb36gZZN{[Xl?			MkTpTWM2OCB;IECuNFAxOyEQvF2=	NHmyfmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{Pid-Mke5PVQ4OzZ:L3G+
Sf9 insect cells	NUjzSnBXTnWwY4Tpc44h[XO\|YYm=		M17oUlYxKG2rboO=	MYLJR\|UxKD1iMD6wNFA{PCEQvF2=	M1S3R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OUGyNVc2Lz5{N{mxNlE4PTxxYU6=
Sf9 insect cells	NYP2c3dETnWwY4Tpc44h[XO\|YYm=		MVi2NEBucW6\|	Ml:wTWM2OCB;IECuNFAxOzRizszN	M2XEcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Sf9 insect cells	MoriSpVv[3Srb36gZZN{[Xl?		NI\pPIc3OCCvaX7z	M3yxVGlEPTBiPTCwMlAxODN2IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN\|c9N2F-
Sf9 cells	MU\GeY5kfGmxbjDhd5NigQ>?		M3jKO\|YxKG2rboO=	MmLFTWM2OCB;IECuNFAxPCEQvF2=	Mn3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
Sf9 cells	M4XhVmZ2dmO2aX;uJIF{e2G7		MVu2NEBucW6\|	MV7JR\|UxKD1iMD6wNFA2KM7:TR?=	MomyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
Ramos cells	NVXtNoJoTnWwY4Tpc44h[XO\|YYm=		MXqxJIg>	NILBU3RKSzVyIE2gNE4xODB3IN88US=>	MmDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
Sf9 cells	MlrWSpVv[3Srb36gZZN{[Xl?		M{DKO\|YxKG2rboO=	MV7JR\|UxKD1iMD6wNFEh\|ryP	NGnUUpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC3O\|YxQCd-M{CwO\|c3ODh:L3G+
Pfeiffer cells	M{jaXmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MmTzO\|IhcA>?	M2jkfmdKPTBiPTCwMlAxOiEQvF2=	M3XPVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUG1NlkyLz5{NEmxOVI6OTxxYU6=
B cells	NUCxS4E4TnWwY4Tpc44h[XO\|YYm=		NVnLeVlQOSCq	NUXzWHRUUUN3MDC9JFAvODB2NjFOwG0>	M{fnZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkmwPVg5Lz5\|MEK5NFk5QDxxYU6=
Sf9 insect cells	NU\XbFlFTnWwY4Tpc44h[XO\|YYm=		NUP6S2E6OiC2bzC2NEBucW6\|	NYXwPHVIU2liPTCwMlAxPDhizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
Ramos cells	MWrGeY5kfGmxbjDhd5NigQ>?		NVXkO5VsOSCq	NWrW[XJ2UUN3MDC9JFAvODB5NTFOwG0>	NF\xbnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxOVI6OSd-MkS5NVUzQTF:L3G+
Sf9 insect cells	MlHwSpVv[3Srb36gZZN{[Xl?		NH3HS2w3OCCvaX7z	M4fpTGlEPTBiPTCwMlAxQCEQvF2=	NH;peYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
TMD8 cells	MkfiRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M135RVczKGh?	Mn34TWM2OCB;IECuNFEh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
CD19+ B cells	MkjMSpVv[3Srb36gZZN{[Xl?		M4\RVlEhcA>?	NFTHS5VKSzVyIE2gNE4xOTJizszN	MmfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NUe5PFIoRjJ7NEW3PVgzRC:jPh?=
Sf9 insect cells	Mmj4SpVv[3Srb36gZZN{[Xl?		NFfHUZQ3OCCvaX7z	NETGd3lKSzVyIE2gNE4xOTJizszN	NIK5fmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	MlTPSpVv[3Srb36gZZN{[Xl?		MkLJNUBp	M2XEd2lEPTBiPTCwMlAyPCEQvF2=	MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
Sf9 insect cells	MVPGeY5kfGmxbjDhd5NigQ>?		NFmycocyKGh?	NHXr[nRKSzVyIE2gNE4xOTR2IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTdzNUCyN{c,Ojl5MUWwNlM9N2F-
Sf9 insect cells	MoLxSpVv[3Srb36gZZN{[Xl?		MoTIOlAhdWmwcx?=	NWS5c4lEUUN3MDC9JFAvODF4MTFOwG0>	NEHlc5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG0OlE{Pid-MkmxOFYyOzZ:L3G+
HCC827 cells	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NUniemVqPzJiaB?=	NXzYb3ZiUUN3MDC9JFAvODN7IN88US=>	M3rZe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{O0OVgyLz5{OEezOFU5OTxxYU6=
PC9 cells	M3\4UGZ2dmO2aX;uJIF{e2G7		NH3wdVc4OiCq	NHiye5dIUTVyIE2gNE4xPSEQvF2=	NHnKd3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
Sf9 cells	Ml;vSpVv[3Srb36gZZN{[Xl?		MoPvOlAhdWmwcx?=	M4Pwd2lEPTBiPTCwMlEh\|ryP	MkPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByME[xOFMoRjNyMEC2NVQ{RC:jPh?=
H3255 cells	MX;GeY5kfGmxbjDhd5NigQ>?		NEDaTJY4OiCq	NUPEfHNHT0l3MDC9JFAvOTFizszN	MnTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
BaF3 cells	MXPGeY5kfGmxbjDhd5NigQ>?		NFf0OXc4OiCq	M2XwfmdKPTBiPTCwMlEzKM7:TR?=	NX7yOG4zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N\|A2PTNpPkK2OlMxPTV\|PD;hQi=>
BAF3 cells	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MnuyO\|IhcA>?	NH\NfVhIUTVyIE2gNE4yOiEQvF2=	MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9 insect cells	Mkf6SpVv[3Srb36gZZN{[Xl?		MVq2NEBucW6\|	M1HTfmlEPTBiPTCwMlEzOyEQvF2=	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
Sf9 insect cells	NVG3SnJqTnWwY4Tpc44h[XO\|YYm=		NXjHflMxPjBibXnudy=>	MkLBTWM2OCB;IECuNVQ3KM7:TR?=	M{HwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
BAF3 cells	MV7GeY5kfGmxbjDhd5NigQ>?		NUO2[I9iPzJiaB?=	M1vndWdKPTBiPTCwMlE3KM7:TR?=	MlXIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
Sf9 cells	MWnGeY5kfGmxbjDhd5NigQ>?		MlPqOlAhdWmwcx?=	NUfVfmJWUUN3MDC9JFAvOiEQvF2=	MmW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUi1OFcoRjJzOUW4OVQ4RC:jPh?=
MV411 cells	NEezOXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MWTHTVUxKD1iMD6yOUDPxE1?	M2DkbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
MV4-11 cells	M3PIOWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4LOelczKGh?	MmfHS2k2OCB;IECuN\|Mh\|ryP	MmX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4M{C1OVMoRjJ4NkOwOVU{RC:jPh?=
MV4-11 cells	NVL4OYZlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NWnYZpBjPzJiaB?=	NUXIVVYyT0l3MDC9JFAvOzNizszN	NUDydZZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
DOHH2 cells	M1TH[GN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYq1THpXPzJiaB?=	NFTveJhIUTVyIE2gNE41OSEQvF2=	NUDUcWpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVUzQTFpPkK0PVE2OjlzPD;hQi=>
HCC827 cells	M{XRfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWq5OkBp	MUnFR\|UxKD1iMD60OUDPxE1?	NXTCSWw4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
SU-DHL6 cells	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		M1\yWlczKGh?	NX:5TY1bT0l3MDC9JFAvPThizszN	MnvOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
M07e cells	MknzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MlHLS2k2OCB;IECuOVkh\|ryP	MlK2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
NCI-H1975 cells	NXrKc24zSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUHhOmFxQTZiaB?=	NF7oU3BGSzVyIE2gNE43PCEQvF2=	NGPrXoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N\|U4PSd-Mki4OVM2PzV:L3G+
SU-DHL-2 cells	NUO1XI5oT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NX7YbHJ2T0l3MDC9JFAvPjRizszN	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDNzNUW5O{c,Ojh\|MUW1PVc9N2F-
HEK293T cells	NXf4WVdbTnWwY4Tpc44h[XO\|YYm=		NV\mXJlCOSCq	MVzJR\|UxKD1iMD65JO69VQ>?	MnTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OECyOlEoRjJ6MkiwNlYyRC:jPh?=
Ramos cells	NWO2emx2SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NUDnWYxnPzJiaB?=	M1vUUGlEPTBiPTCwMlkzKM7:TR?=	M2THdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{G1NFI{Lz5{OUexOVAzOzxxYU6=
BA/F3 cells	MlrLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NVztXXFiPzJiaB?=	MofoTWM2OCB;IEGg{txO	Mn3uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{NUi1NlEoRjJ4MkW4OVIyRC:jPh?=
WSU-NHL cells	MWTDfZRwfG:6aXPpeJkh[XO\|YYm=		MUO3NkBp	NIj2cVBIUTVyIE2gNU4xQSEQvF2=	MkHnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUWyPVEoRjJ2OUG1NlkyRC:jPh?=
NCI-H1975 cells	MVvGeY5kfGmxbjDhd5NigQ>?		NFi2OJU4OiCq	NV;n[\|ZOT0l3MDC9JFEvOiEQvF2=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 cells	MlfZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		MVm3NkBp	M121cWlEPTBiPTCxMlI4KM7:TR?=	NECzdYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEezOFU5OSd-Mki3N\|Q2QDF:L3G+
Raji cells	NWqxdXpNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		Mkf1OFghcA>?	Ml3vTWM2OCB;IEGuOFkh\|ryP	MnXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3NkeyPVUoRjJ7NU[3Nlk2RC:jPh?=
Pfeiffer cells	NHn3T\|BIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M{PabWdKPTBiPTCxMlYh\|ryP	M17JPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
A431 cells	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NXP2OZRGQTZiaB?=	NVHYZZh5TUN3MDC9JFIvOzhizszN	MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6NUO1O\|UoRjJ6OEWzOVc2RC:jPh?=
BAF3 cells	NHrj[WlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NG\HU284OiCq	MWrHTVUxKD1iMj61JO69VQ>?	NVL6WmgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
U937 cells	NIj5enpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			M3TRO2dKPTBiPTCyMlkh\|ryP	M3TScVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{G1OVk4Lz5{OEOxOVU6PzxxYU6=
NB4 cells	NYnETXNoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M17Y[WdKPTBiPTCzJO69VQ>?	NVzwVXNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizNVU2QTdpPkK4N\|E2PTl5PD;hQi=>
Ramos cells	MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NVezUlVGT0l3MDC9JFMvPCEQvF2=	MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
SKM1 cells	M4jkVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			MYfHTVUxKD1iMz62JO69VQ>?	MkXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
U2932 cells	NWfYbIhjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			M4nuPGdKPTBiPTC0MlQh\|ryP	NFTRSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOxOVU6Pyd-MkizNVU2QTd:L3G+
Ramos cells	NH7vUHZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M2LGR\|czKGh?	NHzsVGlKSzVyIE2gOU4yPCEQvF2=	NX\XN3poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
Ramos cells	MnvkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NVnNcVM6PDhiaB?=	NEPONnRKSzVyIE2gOU4yPCEQvF2=	NF;SOos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m1OlA{Pyd-Mke5OVYxOzd:L3G+
Ramos cells	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NVeyOmY5PDhiaB?=	M12ydGlEPTBiPTC1Mlg5KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|Mkm0Okc,Ojh2M{K5OFY9N2F-
Ramos cells	NWLpO2JUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		MWK3NkBp	NFHwR2pKSzVyIE2gOk43OiEQvF2=	NVTX[GNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOFYyOzZpPkK5NVQ3OTN4PD;hQi=>
K562 cells	NIX6TJBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		MkDzOFghcA>?	NWGxOJlpUUN3MDC9JFcvPSEQvF2=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB5N{[wPEc,OzByN{e2NFg9N2F-
HL60 cells	MkfERY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NYTkendTPDhiaB?=	M2C3SGlEPTBiPTC4JO69VQ>?	NXfhUYZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|c3ODhpPkOwNFc4PjB6PD;hQi=>
Ramos cells	MoDORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4ew[VQ5KGh?	NXfDWZpJUUN3MDC9JFgvOTFizszN	NIHtT5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{Pid-Mke5PVQ4OzZ:L3G+
Ramos cells	M2r2WWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NGTHdWo1QCCq	NGK1bpZKSzVyIE2gPE4zPiEQvF2=	M2fDWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NU[3Nlk2Lz5{OUW2O\|I6PTxxYU6=
OCI-AML3 cells	Mn3sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGnnT4ZIUTVyIE2gPU4zKM7:TR?=	MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|MUW1PVcoRjJ6M{G1OVk4RC:jPh?=
BAF3 cells	M2i2NGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGOyPYI4OiCq	NIXXTlNIUTVyIE2gNVAh\|ryP	NG\6WJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNFU2Oyd-Mk[2N\|A2PTN:L3G+
BAF3 cells	M{iyemFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		MWK3NkBp	MnH5S2k2OCB;IEGwJO69VQ>?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3 cells	M{nKOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4\uOlczKGh?	NHrER3NIUTVyIE2gNVAh\|ryP	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NAMALWA cells	M4jBTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M4DyZ\|czKGh?	MUDJR\|UxKD1iMUCuOFUh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF2NkGzOkc,OjlzNE[xN\|Y9N2F-
Ramos cells	NVXMNXg1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|YYm=		NEn3dJc1QCCq	NVnYWlVpUUN3MDC9JFEzNjZizszN	NHruRoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		Mn3zOFghcA>?	M{PwNmlEPTBiPTCxOE4zKM7:TR?=	NXnHU5ZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwO\|c3ODhpPkOwNFc4PjB6PD;hQi=>
Raji cells	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		MUi0PEBp	NFPqUHFKSzVyIE2gNVUvOiEQvF2=	MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|YoRjJ5OUm0O\|M3RC:jPh?=
MIAPaCa2 cells	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		MmrlN{Bl[Xm\|	M4PtbmlEPTBiPTCxOk43KM7:TR?=	NWTZPZo1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewO\|czOjhpPkK3NFc4OjJ6PD;hQi=>
HeLa cells	Mn7JR5l1d3SxeHnjbZR6KGG\|c3H5		NWS0VpJ3OyCmYYnz	MXPJR\|UxKD1iMU[uPEDPxE1?	NHSxUIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C3O\|IzQCd-MkewO\|czOjh:L3G+
Raji cells	MnvSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		M4T5ZlQ5KGh?	MknMTWM2OCB;IEG5MlMh\|ryP	NGDjXJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxNlE4PSd-Mke5NVIyPzV:L3G+
Raji cells	M4TY[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		M2\pVFQ5KGh?	M4DLOmlEPTBiPTCxPU4{KM7:TR?=	M3KzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEOyPVQ3Lz5{OESzNlk1PjxxYU6=
Raji cells	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>?		NFPKbI04OiCq	MVnJR\|UxKD1iMUmuOUDPxE1?	NYTUd5lURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwNFYyPDNpPkOwNFA3OTR\|PD;hQi=>
Raji cells	NEnNZpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		M1H2TFQ5KGh?	NVPHOYVNUUN3MDC9JFE6NjVizszN	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl3NkCzO{c,Ojd7NU[wN\|c9N2F-
NAMALWA cells	M{\HT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7		NHP2Umk4OiCq	M{S5OmlEPTBiPTCxPU43KM7:TR?=	NFyzWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECwOlE1Oyd-M{CwNFYyPDN:L3G+
A2780 cells	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		MorON{Bl[Xm\|	MYjFR\|UxKD1iMkCuNUDPxE1?	MkjMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyN{eyNlgoRjJ5MEe3NlI5RC:jPh?=
Raji cells	NETyWIdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?=		NUnHfYp4PzJiaB?=	Ml20TWM2OCB;IEKwMlg5KM7:TR?=	M4fGUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUS2NVM3Lz5{OUG0OlE{PjxxYU6=
A549 cells	MkLBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl?		NXv0XotWPzJiaB?=	Mk\2TWM2OCB;IEKxMlc6KM7:TR?=	NX3x[od6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3N\|Q2QDFpPkK4O\|M1PThzPD;hQi=>
SW480 cells	NV:5ZXZVS3m2b4TvfIlkcXS7IHHzd4F6		M4jR[VMh\GG7cx?=	NFX1OXNKSzVyIE2gNlUvPiEQvF2=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB5N{KyPEc,OjdyN{eyNlg9N2F-
Ramos cells	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		MkfSNlQhcA>?	NX\teZdzUUN3MDC9JFI5NjdizszN	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ5NE[3OUc,Ojh{N{S2O\|U9N2F-

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pEGFR(Tyr1068) / EGFR; PubMed: 28061447 Oncotarget Ibrutinib inhibitory effects on EGFRY1068 auto-phosphorylation in the HCC827 cell line at different time points by removal of drug after 4 h pretreatment. pBTK / pPLCγ2 / pAKT / pERK / pJNK; PubMed: 23940282 Blood Mino (left panel) or Jeko1 (right panel) cells pretreated with vehicle or ibrutinib 10, 100, or 1000 nM were either stimulated with anti-IgM, CXCL12, or CXCL13 or treated with medium (Med) for 15 minutes and then immunoblotted for pBTK, pPLCγ2, pAKT, pERK, and pJNK.	28061447 23940282
Immunofluorescence	CD11b; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were pretreated with ibrutinib (1 μM) or vehicle (1% DMSO) for 30 min, followed by treatment with LPS (1 μg/ml) or PBS for 5.5 h and immunostaining with an anti-CD11b antibody. Scale bar = 20 μm. COX-2; PubMed: 30231870 J Neuroinflammation BV2 microglial cells were treated with vehicle (1% DMSO) or ibrutinib (1 μM) for 30 min, followed by PBS or LPS (1 μg/ml) for 5.5 h, and immunocytochemistry was conducted with anti-CD11b and anti-COX-2 antibodies.	30231870
ELISA	hTNFα; PubMed: 26627823 J Biol Chem PBMs were isolated and pretreated with 1, 5, or 10 μm ibrutinib (IB) or left untreated (UT, −). Pretreated PBMs were incubated for 24 h in 96-well plates precoated without (PBS) or with 10 μg/ml whole human IgG. Cleared supernatants were collected and analyzed by ELISA for TNFα (n = 3). IL-10; PubMed: 27792904 Virology LMP2A-negative (vector.1/.2) and -positive (express LMP2A) B cell lines were incubated in the absence or presence of increasing concentrations of Ibrutinib for 24 hours and supernatants were isolated for analysis using an IL-10 ELISA.	26627823 27792904

体内試験

In a collagen-induced arthritis model, Ibrutinib significantly reduces clinical arthritis scores reflecting paw swelling and joint inflammation by inhibiting B-cell activation. In a MRL-Fas(lpr) lupus model, Ibrutinib reduces renal disease and autoantibody production. ^[1] In an adoptive transfer TCL1 mouse model of CLL, Ibrutinib (25 mg/kg/day) causes a transient early lymphocytosis, and delays CLL disease progression. ^[4]

お薦めの試験操作（参考用のみ）

キナーゼ試験： ^[1]	- 合併 Kinase Assays : In vitro kinase IC50 values are measured using ³³P filtration binding assay after 1 hour incubation of kinase, ³³P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology.
細胞試験： ^[2]	- 合併細胞株： Chronic lymphocytic leukemia (CLL) cells 濃度： 0.01-100 μM 反応時間： 48 hours 実験の流れ： MTT (3'[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assays are performed to determine cytotoxicity. Briefly, cells (CLL B cells or healthy volunteer T cells or NK cells) are incubated for 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline. Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Cell viability is also measured at various time points with the use of annexin/PI flow cytometry. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD. (参考用のみ)
動物試験： ^[1]	- 合併動物モデル： MRL-Fas(lpr) lupus model and collagen-induced arthritis model. 投薬量： ≤50 mg/kg 投与方法： Administered via p.o. (参考用のみ)

参考

[4] Ponader S, et al. Blood. 2012, 119(5), 1182-1189.

- 合併

溶解度 (25°C)

体外	DMSO	88 mg/mL (199.77 mM)
	Water	Insoluble
	Ethanol	'45 mg/mL warmed '45
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O 混合させたのち直ちに使用することを推奨します。	10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

分子量	440.5
化学式	C₂₅H₂₄N₆O₂
CAS No.	936563-96-1
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04665115	Withdrawn	Drug: Ibrutinib\|Other: Quality-of-Life Assessment	Asymptomatic COVID-19 Infection Laboratory-Confirmed\|B-Cell Neoplasm\|Chronic Lymphocytic Leukemia\|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma\|Mantle Cell Lymphoma\|Marginal Zone Lymphoma\|Small Lymphocytic Lymphoma\|Symptomatic COVID-19 Infection Laboratory-Confirmed\|Waldenstrom Macroglobulinemia	Academic and Community Cancer Research United\|National Cancer Institute (NCI)	December 2021	Phase 2
NCT05105841	Recruiting	Drug: Venetoclax\|Drug: Ibrutinib\|Drug: Obinutuzumab	Chronic Lymphocytic Leukemia (CLL)\|Small Lymphocytic Lymphoma (SLL)	AbbVie	November 8 2021	Phase 2
NCT04876092	Recruiting	Drug: JNJ-67856633\|Drug: Ibrutinib	Leukemia Lymphocytic Chronic B-Cell\|Lymphoma Non-Hodgkin	Janssen Research & Development LLC	July 28 2021	Phase 1
NCT04294641	Recruiting	Drug: Ibrutinib	Chronic GVHD	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	May 10 2021	Phase 2
NCT04514393	Not yet recruiting	Drug: Methotrexate\|Drug: Ibrutinib\|Drug: Temozolomide	Primary Central Nervous System Lymphoma\|PCNSL\|Non Hodgkin Lymphoma	Huiqiang Huang\|Guangdong 999 Brain Hospital\|Nanfang Hospital of Southern Medical University\|Xian-Janssen Pharmaceutical Ltd.\|Sun Yat-sen University	December 1 2020	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須
*大学・企業名:
*名前:
*電子メール:
*電話番号:
*内容:

よくある質問（FAQ）

質問1：
How to reconstitute the compound S2680 for in vivo studies?
回答：
For in vivo study, we suggest to use 5% DMSO+30% PEG 300+5% Tween 80+ddH2O up to 10mg/ml.

研究分野別

製品類型

Ibrutinib (PCI-32765)

文献中Selleckの製品使用例(483)

製品安全説明書

Target Protein Ligand阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ibrutinib (PCI-32765) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技術サポート

よくある質問（FAQ）